33336227|t|Comparative Analysis of Different Definitions of Amyloid-beta Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer.
33336227|a|Amyloid-beta (Abeta) positivity is defined using different biomarkers and different criteria. Criteria used in symptomatic patients may conceal meaningful early Abeta pathology in preclinical Alzheimer. Therefore, the description of sensitive cutoffs to study the pathophysiological changes in early stages of the Alzheimer's continuum is critical. Here, we compare different Abeta classification approaches and we show their performance in detecting pathophysiological changes downstream Abeta pathology. We studied 368 cognitively unimpaired individuals of the ALFA+ study, many of whom in the preclinical stage of the Alzheimer's continuum. Participants underwent Abeta PET and CSF biomarkers assessment. We classified participants as Abeta -positive using five approaches: (1) CSF Abeta42 < 1098 pg/ml; (2) CSF Abeta42/40 < 0.071; (3) Abeta PET Centiloid > 12; (4) Abeta PET Centiloid > 30 or (5) Abeta PET Positive visual read. We assessed the correlations between Abeta biomarkers and compared the prevalence of Abeta positivity. We determined which approach significantly detected associations between Abeta pathology and tau/neurodegeneration CSF biomarkers. We found that CSF-based approaches result in a higher Abeta-positive prevalence than PET-based ones. There was a higher number of discordant participants classified as CSF Abeta-positive but PET Abeta-negative than CSF Abeta-negative but PET Abeta-positive. The CSF Abeta 42/40 approach allowed optimal detection of significant associations with CSF p-tau and t-tau in the Abeta-positive group. Altogether, we highlight the need for sensitive Abeta -classifications to study the preclinical Alzheimer's continuum. Approaches that define Abeta positivity based on optimal discrimination of symptomatic Alzheimer's disease patients may be suboptimal for the detection of early pathophysiological alterations in preclinical Alzheimer.
33336227	49	61	Amyloid-beta	Gene	351
33336227	146	155	Alzheimer	Disease	MESH:D000544
33336227	157	169	Amyloid-beta	Gene	351
33336227	171	176	Abeta	Gene	351
33336227	280	288	patients	Species	9606
33336227	318	323	Abeta	Gene	351
33336227	349	358	Alzheimer	Disease	MESH:D000544
33336227	471	482	Alzheimer's	Disease	MESH:D000544
33336227	533	538	Abeta	Gene	351
33336227	646	651	Abeta	Gene	351
33336227	778	789	Alzheimer's	Disease	MESH:D000544
33336227	824	829	Abeta	Gene	351
33336227	895	900	Abeta	Gene	351
33336227	942	949	Abeta42	Gene	351
33336227	972	979	Abeta42	Gene	351
33336227	996	1001	Abeta	Gene	351
33336227	1026	1031	Abeta	Gene	351
33336227	1058	1063	Abeta	Gene	351
33336227	1127	1132	Abeta	Gene	351
33336227	1175	1180	Abeta	Gene	351
33336227	1266	1271	Abeta	Gene	351
33336227	1286	1289	tau	Gene	4137
33336227	1290	1307	neurodegeneration	Disease	MESH:D019636
33336227	1378	1383	Abeta	Gene	351
33336227	1496	1501	Abeta	Gene	351
33336227	1519	1524	Abeta	Gene	351
33336227	1543	1548	Abeta	Gene	351
33336227	1566	1571	Abeta	Gene	351
33336227	1590	1601	Abeta 42/40	Gene	351
33336227	1697	1702	Abeta	Gene	351
33336227	1767	1772	Abeta	Gene	351
33336227	1815	1826	Alzheimer's	Disease	MESH:D000544
33336227	1861	1866	Abeta	Gene	351
33336227	1925	1944	Alzheimer's disease	Disease	MESH:D000544
33336227	1945	1953	patients	Species	9606
33336227	2045	2054	Alzheimer	Disease	MESH:D000544
33336227	Association	351	4137
33336227	Association	MESH:D000544	351
33336227	Association	MESH:D019636	351

